Our Mission

 

At Vicarius Pharma, we commercialize novel specialty, orphan/rare and hospital therapies in European markets on behalf of our partners.

Our bespoke market entry solutions enable our partners to successfully grow their business while keeping control of their destiny.

 

Executive Team

 

We are a team of highly experienced senior executives with unparalleled networks. We know the European pharmaceutical market inside out and leverage our expertise and connections for the success of our partners’ products.

 

Working with Vicarius Pharma means that, from day one of the partnership, our partners’ assets get the full dedication of a ready-now, expert European Executive Team.

 

CEO and Member of the Board

Pre-Approval Regulatory Affairs

Fran Brewer is a Regulatory Affairs executive & consultant with broad international and therapeutic expertise. She has extensive experience in the development of regulatory strategies and has achieved a number of approvals under challenging circumstances. In addition, Fran Brewer has developed successful strategies for orphan drug indications including rare childhood disorders.

Chief Compliance Officer

Vice President, Market Access

Fabiana Lacerca-Allen has more than 25 years of experience in the pharmaceutical, biotech and medical device industry. She has been in a number of key strategic leadership positions in charge of legal and compliance teams, and recently as an Audit Committee member of the Board of Directors of a publicly traded company.



Farzana Malik trained as health economist in the UK and is a senior market access leader with extensive experience in strategic pricing, outcomes research and market access. She has a track record of successful pricing and reimbursement approvals for biotech and medical devices across Europe and other geographies.



Chief Medical/Scientific Officer

Chief Financial Officer

 

Rossella Medori is a senior executive with proven leadership skills in international research, clinical development and medical affairs and has demonstrated operational expertise in academia as well as major pharmaceutical and biotechnology companies. She has extensive experience in building strong support networks with key stakeholders in the biotechnology and pharmaceutical sectors.

Hans-Peter Rudolf is a senior Financial Executive with extensive experience in international finance, administration, and public accounting. He has a solid track record in supporting sustainable business growth through tailored finance and cost management, strong internal controls, as well as continuous efficiency improvements.

 

Post-Approval Regulatory Affairs

Barbara Briggs maximizes the commercial potential of pharmaceutical products by focusing on the core company position to facilitate regional and country product labels. In-depth knowledge of the European regulatory landscape has allowed her to successfully manage and implement a number of high-profile labelling and risk management projects.

Head of Business Development,

Legal & External Affairs

Francis Marsland is legal counsel and a senior life science executive, with extensive experience in legal, P&L, general management, BD, HR and external relations.
He has a comprehensive expertise in international corporate transactions, business development and corporate affairs.




Vice President,

Head of Commercial Strategy

Markus Steinmayr is an international marketing & sales executive with extensive experience in biopharma start-ups, pharmaceutical corporations and medical devices companies. He successfully commercialized a number of products in oncology and multiple sclerosis, and has built and managed commercial country and regional organizations in Europe, including DACH and Central Eastern Europe.

Board of Directors

James C. Mullen

Chairman

James C. Mullen brings over 35 years of experience in the pharmaceutical and biotechnology industries, over 25 of which have been spent at the executive level.

 

James C. Mullen served as CEO and a member of the Board of Directors of Patheon Inc. from 2011 to 2017, and as President and CEO of Biogen, one of the world’s leading biotechnology companies, from 2000 to 2010. From 1996 to 1999 he was Vice President of International Operations for Biogen and resided in Europe as he led the development of Biogen’s commercial operations outside the United States.

 

James C. Mullen served on the Board of Directors of Biogen until June 2010 and until April 2015, on the Board of Directors of Perkin Elmer, Inc. Currently he serves on the Board of Directors of Insulet, Inc. and was appointed Chairman of the Board of Directors of Editas Medicine, Inc. in March 2018.

 

Hans Peter Hasler

Vice Chairman

Hans Peter Hasler is the founder and CEO of Vicarius Pharma. He is a senior executive with an international track record and in-depth operational, commercial and general management expertise. He also acts as top-level advisor to the life-science industry.

 

In his career, he has managed the growth of leading players in the pharmaceutical industry and successfully launched several blockbuster drugs.

 

Mr. Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland and Director of the Boards of Dr. Reddy’s Laboratories in Hyderabad and Minerva Neuroscience Inc, Boston.

 

Michel Lagarde

Michel Lagarde is President, Pharma Services, at Thermo Fisher Scientific Inc. From May 2016 to August 2017, he was President and COO of Patheon Inc. He joined Patheon in 2016 from JLL Partners, a leading middle market private equity firm with a track record across several growing sectors, including healthcare, business/financial services, building products and aerospace/defense. He has been working with several of JLL’s portfolio companies in the healthcare and pharma services sectors as managing director, including Patheon.

 

Michel Lagarde served as a member of Patheon’s Board of Directors from 2011 to 2016. He earned a B.B.A from European University Antwerp and an Executive Master in Finance & Control from the University of Maastricht & Amsterdam.

 

Our Values

 

Six principles describe how we work at Vicarius Pharma.

In everything we do, we aim to excel by living the following values:

 

Ownership

Integrity

We own our partners’ success, and invest and execute at risk.

We believe that trust and reliability are the fundamentals of our work.

 

Transparency

Performance

We share what we know, and we address issues early and transparently.

We are driven by results and are relentless in our pursuit of the best outcome.

Alignment

Agility

We adopt our partners’ goals as our own and create win-win solutions.

We provide flexible and tailored solutions, and we are nimble and fast.

Our History

 

Incorporated in April 2016 in the Greater Zurich Area in Switzerland,

Vicarius Pharma was founded to offer research-driven pharmaceutical, biotech and medical devices companies tailored and attractive European market entry options.

 

Vicarius Pharma addresses the risks and disadvantages of existing European market entry strategies (out-licensing or go-it-alone) by offering novel and highly flexible commercial partnership models and building and managing rightsized European go-to-market organizations on behalf of our partners.

 

The name „Vicarius“, lat.: representative/deputy, reflects our shared-value approach. We think and act on our partners’ behalf to maximize the potential for commercial success of their product in Europe, while they focus on the domestic market and keep their strategic options open.